HLA-B*5701 Typing

Last Modified: 3/27/2019 3:48:47 PM

Medical Necessity Documentation:  
Client Notes:  
Patient Preparation:  
Specimen Requirements: 5.0 mL Whole Blood in a Lavender Top Tube - EDTA
Collection Instructions:  
Minimum Volume: 3.0 mL Whole Blood
Transport & Storage: Temperature/Stability: 7 days Ambient
7 days Refrigerated
Rejection Criteria: Frozen
Reference Range:

Refer to Interpretive Results

Critical Ranges:  
Test Comments: Additional testing by Sequence Based Typing (SBT) may be performed when necessary.

Limitations: A negative result does not rule out the risk for ABC HSR and clinical vigilance should be maintained regardless of the result. The frequency of HLA/-B5701 is approximately 8% in Caucasians and 2% in African Americans.
Methodology: Polymerase Chain Reaction (PCR) • Sequence Specific Oligonucleotide Probes (SSO)
Clinical Significance:

Abacavir therapy for HIV treatment is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong association with the HLA-B*5701 allele. HLA-B*5701 typing can be used for genetic risk stratification prior to initiation of abacavir therapy.

Custom Panel: No


Turn Around Time: 6 to 7 days
Days Performed: Sunday, Monday, Tuesday, Wednesday, Thursday, Friday, Saturday
Sites Performed: Quest - Chantilly
PHL Test Code: H5701
EPIC Test Code: LAB2940
Send Out Test Code: 19774
Alternate Test Names: HLA - B 5701 Type; HLA B 5701 Type; HLA-b 5701; HLA-B 5701 Type
Included Tests:  
CPT Coding: 81381

Go back to the top of the page.